SummaryThis is a dose escalation and expansion trial. In part 1
of the study, participants will receive an intravenous dose of GSK3745417 alone, at one week intervals. In part 2, GSK3745417 will be co-administered with 200mg IV pembrolizumab once every three weeks.
This trial is treating patients with solid cancers.
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors